Presentation of Lipid Antigens Cd1a Is Essential for Its Intersection And

Total Page:16

File Type:pdf, Size:1020Kb

Presentation of Lipid Antigens Cd1a Is Essential for Its Intersection And Early Recycling Compartment Trafficking of CD1a Is Essential for Its Intersection and Presentation of Lipid Antigens This information is current as Manuela Cernadas, Marco Cavallari, Gerald Watts, Lucia of September 28, 2021. Mori, Gennaro De Libero and Michael B. Brenner J Immunol 2010; 184:1235-1241; Prepublished online 21 December 2009; doi: 10.4049/jimmunol.0804140 http://www.jimmunol.org/content/184/3/1235 Downloaded from References This article cites 33 articles, 11 of which you can access for free at: http://www.jimmunol.org/content/184/3/1235.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on September 28, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2010 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Early Recycling Compartment Trafficking of CD1a Is Essential for Its Intersection and Presentation of Lipid Antigens Manuela Cernadas,*,1 Marco Cavallari,†,1 Gerald Watts,‡ Lucia Mori,† Gennaro De Libero,†,2 and Michael B. Brenner‡,2 A major step in understanding differences in the nature of Ag presentation was the realization that MHC class I samples peptides transported to the endoplasmic reticulum from the cytosol, whereas MHC class II samples peptides from lysosomes. In contrast to MHC class I and II molecules that present protein Ags, CD1 molecules present lipid Ags for recognition by specific T cells. Each of the five members of the CD1 family (CD1a–e) localizes to a distinct subcompartment of endosomes. Accordingly, it has been widely assumed that the distinct trafficking of CD1 isoforms must also have evolved to enable them to sample lipid Ags that traffic via Downloaded from different routes. Among the CD1 isoforms, CD1a is unusual because it does not have a tyrosine-based cytoplasmic sorting motif and uniquely localizes to the early endocytic recycling compartment. This led us to predict that CD1a might have evolved to focus on lipids that localize to early endocytic/recycling compartments. Strikingly, we found that the glycolipid Ag sulfatide also localized almost exclusively to early endocytic and recycling compartments. Consistent with colocalization of CD1a and sulfatide, wild-type CD1a molecules efficiently presented sulfatide to CD1a-restricted, sulfatide-specific T cells. In contrast, CD1a:CD1b tail chimeras, that retain the same Ag-binding capacity as CD1a but traffic based on the cytoplasmic tail of CD1b to lysosomes, failed http://www.jimmunol.org/ to present sulfatide efficiently. Thus, the intracellular trafficking route of CD1a is essential for efficient presentation of lipid Ags that traffic through the early endocytic and recycling pathways. The Journal of Immunology, 2010, 184: 1235–1241. he CD1 family of Ag-presenting molecules is unique in its d isoforms is determined by their unique cytoplasmic tail tyrosine- ability to present lipid, glycolipid, and lipopeptide Ags to based sorting motif (2). The intracellular localization of the CD1b T CD1-restricted T cells. In contrast to MHC-restricted Ag isoform, for example, is almost exclusively in the lysosomal com- presentation, CD1 molecules are functionally nonpolymorphic and partment. This CD1b localization is mediated by the adaptor protein have been shown to present both exogenous microbial Ags as well as AP-3 through interactions with the cytoplasmic tyrosine-based by guest on September 28, 2021 endogenous lipid ligands (1). Similar to MHC class I molecules, CD1 motif of CD1b (3). molecules are noncovalently associated with b2-microglobulin. The CD1a isoform is almost exclusively expressed on pro- CD1a, b, and c molecules are primarily expressed on professional fessional APC, including Langerhans cells (LCs) and other myeloid APCs and have been implicated in adaptive immunity against mi- dendritic cell (DC) subsets (2). CD1a is distinct among the CD1 crobial lipids. In contrast, CD1d-restricted NK T cells are innate- isoforms in that it does not contain a tyrosine-based cytoplasmic like lymphocytes that may bridge the innate and adaptive immune motif. CD1a has been shown to localize intracellularly to the en- system. Each of the five members of the human CD1 family—CD1a, docytic recycling compartment (ERC) (4, 5). In contrast to CD1b, b, c, d, and e—has a distinct cellular distribution and intracellular CD1a internalization into endosomes is independent of clathrin or trafficking pattern. The intracellular localization of the CD1b, c, and dynamin. Once internalized, CD1a molecules follow a Rab22a- and ADP ribosylation factor 6-dependent recycling pathway (5). Under *Division of Pulmonary and Critical Care Medicine and ‡Division of Rheumatology, steady-state conditions, CD1a is not found to localize to late en- Immunology and Allergy, Brigham and Women’s Hospital, Harvard Medical School, dosomes (LEs) or lysosomes (LYs) (4). Moreover, CD1a molecules † Boston, MA 02115; and Experimental Immunology, Department of Biomedicine, have also been shown to localize in Birbeck granules, which are University Hospital Basel, Basel, Switzerland intracellular compartments unique to LCs that have been demon- 1M.C. and M.C. contributed equally to this work. 2 strated to be subdomains of the endocytic system (6). G.D.L. and M.B.B. contributed equally to this work. Several T cell Ags presented by CD1a have been described in- Received for publication December 11, 2008. Accepted for publication November cluding didehydroxymycobactin, a lipopeptidic Ag isolated from 17, 2009. Mycobacterium tuberculosis, and sulfatide (7, 8). Sulfatide (39- This work was supported by grants from the National Institutes of Health (AI 028973 to M.B.B.), the Swiss National Science Foundation (3100AO-109918), and Roche sulfated b1-D-galactosylceramide) is an endogenous glycolipid Research Foundation (to G.D.L.). highly expressed in neuronal cells, kidney, and pancreas (9–11), and Address correspondence and reprint requests to Dr. Michael B. Brenner, Division of its synthesis is upregulated in DCs upon bacterial infection (12). Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, Harvard Sulfatide can be presented by all group 1 CD1 molecules including Medical School, Smith Building, Room 552, 1 Jimmy Fund Way, Boston, MA 02115. E-mail address: [email protected] mouse and human CD1d (8, 13, and M. Cavallari and G. De Libero, Abbreviations used in this paper: DC, dendritic cell; EEA-1, early endosome Ag-1; ERC, unpublished results). DC pulsed with sulfatide maintained the endocytic recycling compartment; LAM, lipoarabinomannan; LAMP-1, lysosome- ability to stimulate CD1a-restricted T cells over a 3 d period. In associated membrane protein 1; LC, Langerhans cell; LE, late endosome; LY,lysosome; contrast, the ability of the sulfatide-pulsed DC to stimulate CD1b- Trf, transferrin; WT, wild-type. and CD1c-restricted T cells was reduced by ∼75% over the same Copyright Ó 2010 by The American Association of Immunologists, Inc. 0022-1767/10/$16.00 time period. These findings suggest that CD1a has a unique ability www.jimmunol.org/cgi/doi/10.4049/jimmunol.0804140 1236 CD1a TRAFFICKING IS ESSENTIAL FOR LIPID ANTIGEN PRESENTATION to present sulfatide. However, these studies cannot distinguish be- Hercules, CA). Stable clones were isolated by limiting dilution under se- tween higher affinity of CD1a binding for sulfatide versus more lection with 1 mg/ml G418 sulfate (Invitrogen) in DMEM complete media. extensive colocalization of the Ag-presenting molecule with the Ag. Transient transfections were performed with FuGENE 6 (Roche, Basel, Switzerland) as per manufacturer’s instructions. CD1a cell surface ex- In this study, we show that the intracellular localization of the pression was confirmed by flow cytometric staining and intracellular traf- CD1a isoform to the early endocytic system allows it to intersect with ficking by confocal microscopy as detailed below. Monocyte-derived DCs lipids that are primarily or, in the case of sulfatide, almost exclusively, were generated as previously described (15). Briefly, CD14+ monocytes localized in the early endocytic system. This colocalization was were isolated from buffy coats obtained from normal blood donors as per institutional guidelines. Mononuclear cells were isolated with Ficoll-Paque shown to be critical for the sustained ability of CD1a molecules to PLUS (GE Healthcare, Buckinghamshire, U.K.) and monocytes positively stimulate CD1a-restricted T cells. When the same CD1a extracellular selected with CD14 MicroBeads (MACS; Miltenyi Biotec, Auburn, CA). domain was fused to the CD1b tail, redirecting it to LYs, efficient and DCs were differentiated in RPMI 1640 complete media (Life Technologies, prolonged presentation of CD1a lipid Ag was abrogated. This finding Carlsbad, CA), 10% heat-inactivated FCS (HyClone, Logan, UT), 2 mM L- has significant implications for
Recommended publications
  • Human and Mouse CD Marker Handbook Human and Mouse CD Marker Key Markers - Human Key Markers - Mouse
    Welcome to More Choice CD Marker Handbook For more information, please visit: Human bdbiosciences.com/eu/go/humancdmarkers Mouse bdbiosciences.com/eu/go/mousecdmarkers Human and Mouse CD Marker Handbook Human and Mouse CD Marker Key Markers - Human Key Markers - Mouse CD3 CD3 CD (cluster of differentiation) molecules are cell surface markers T Cell CD4 CD4 useful for the identification and characterization of leukocytes. The CD CD8 CD8 nomenclature was developed and is maintained through the HLDA (Human Leukocyte Differentiation Antigens) workshop started in 1982. CD45R/B220 CD19 CD19 The goal is to provide standardization of monoclonal antibodies to B Cell CD20 CD22 (B cell activation marker) human antigens across laboratories. To characterize or “workshop” the antibodies, multiple laboratories carry out blind analyses of antibodies. These results independently validate antibody specificity. CD11c CD11c Dendritic Cell CD123 CD123 While the CD nomenclature has been developed for use with human antigens, it is applied to corresponding mouse antigens as well as antigens from other species. However, the mouse and other species NK Cell CD56 CD335 (NKp46) antibodies are not tested by HLDA. Human CD markers were reviewed by the HLDA. New CD markers Stem Cell/ CD34 CD34 were established at the HLDA9 meeting held in Barcelona in 2010. For Precursor hematopoetic stem cell only hematopoetic stem cell only additional information and CD markers please visit www.hcdm.org. Macrophage/ CD14 CD11b/ Mac-1 Monocyte CD33 Ly-71 (F4/80) CD66b Granulocyte CD66b Gr-1/Ly6G Ly6C CD41 CD41 CD61 (Integrin b3) CD61 Platelet CD9 CD62 CD62P (activated platelets) CD235a CD235a Erythrocyte Ter-119 CD146 MECA-32 CD106 CD146 Endothelial Cell CD31 CD62E (activated endothelial cells) Epithelial Cell CD236 CD326 (EPCAM1) For Research Use Only.
    [Show full text]
  • Mycobacterium Tuberculosis Activation by Human Toll-Like Receptors
    Human Toll-Like Receptors Mediate Cellular Activation by Mycobacterium tuberculosis Terry K. Means, Shuyan Wang, Egil Lien, Atsutoshi Yoshimura, Douglas T. Golenbock and Matthew J. Fenton This information is current as of September 27, 2021. J Immunol 1999; 163:3920-3927; ; http://www.jimmunol.org/content/163/7/3920 Downloaded from References This article cites 32 articles, 17 of which you can access for free at: http://www.jimmunol.org/content/163/7/3920.full#ref-list-1 Why The JI? Submit online. http://www.jimmunol.org/ • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average by guest on September 27, 2021 Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 1999 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. Human Toll-Like Receptors Mediate Cellular Activation by Mycobacterium tuberculosis1 Terry K. Means,* Shuyan Wang,* Egil Lien,† Atsutoshi Yoshimura,† Douglas T. Golenbock,† and Matthew J. Fenton2* Recent studies have implicated a family of mammalian Toll-like receptors (TLR) in the activation of macrophages by Gram- negative and Gram-positive bacterial products.
    [Show full text]
  • Cd1a [O10] Concentrated and Prediluted Monoclonal Antibody 901-3158-061719
    CD1a [O10] Concentrated and Prediluted Monoclonal Antibody 901-3158-061719 Catalog Number: ACI 3158 A, B API 3158 AA VLTM 3158 G20 Description: 0.1, 0.5 mL conc. 6.0 mL, RTU 20 mL, RTU Dilution: 1:100 Ready-to-use Ready-to-use Diluent: Van Gogh Yellow N/A N/A Intended Use: Protocol Recommendations (VALENT® Automated Slide For In Vitro Diagnostic Use Staining Platform) Cont’d: CD1a [O10] is a mouse monoclonal antibody that is intended for Protein Block (Optional): Incubate for 10-20 minutes at RT with Val laboratory use in the qualitative identification of CD1a protein by Background Block. immunohistochemistry (IHC) in formalin-fixed paraffin-embedded Primary Antibody: Incubate for 30 minutes. (FFPE) human tissues. The clinical interpretation of any staining or its Secondary: Incubate for 10 minutes with Val Mouse Secondary. absence should be complemented by morphological studies using proper Linker: Incubate for 10 minutes with Val Universal Linker. controls and should be evaluated within the context of the patient’s Polymer: Incubate for 10 minutes with Val Universal Polymer. clinical history and other diagnostic tests by a qualified pathologist. Chromogen: Incubate for 5 minutes with Val DAB. Summary and Explanation: Counterstain: Counterstain for 5 minutes with Val Hematoxylin. CD1a is a protein of 43 to 49 kDa and is expressed on dendritic cells and cortical thymocytes (1,2). CD1a [O10] staining has been shown to be Protocol Recommendations (intelliPATH FLX® and manual use): useful in the differentiation of Langerhans cells from interdigitating cells. Peroxide Block: Block for 5 minutes with Peroxidazed 1. It has also proved useful for phenotyping Langerhans cell histiocytosis Pretreatment: Perform heat retrieval using Diva or Reveal Decloaker.
    [Show full text]
  • Single-Cell RNA Sequencing Demonstrates the Molecular and Cellular Reprogramming of Metastatic Lung Adenocarcinoma
    ARTICLE https://doi.org/10.1038/s41467-020-16164-1 OPEN Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma Nayoung Kim 1,2,3,13, Hong Kwan Kim4,13, Kyungjong Lee 5,13, Yourae Hong 1,6, Jong Ho Cho4, Jung Won Choi7, Jung-Il Lee7, Yeon-Lim Suh8,BoMiKu9, Hye Hyeon Eum 1,2,3, Soyean Choi 1, Yoon-La Choi6,10,11, Je-Gun Joung1, Woong-Yang Park 1,2,6, Hyun Ae Jung12, Jong-Mu Sun12, Se-Hoon Lee12, ✉ ✉ Jin Seok Ahn12, Keunchil Park12, Myung-Ju Ahn 12 & Hae-Ock Lee 1,2,3,6 1234567890():,; Advanced metastatic cancer poses utmost clinical challenges and may present molecular and cellular features distinct from an early-stage cancer. Herein, we present single-cell tran- scriptome profiling of metastatic lung adenocarcinoma, the most prevalent histological lung cancer type diagnosed at stage IV in over 40% of all cases. From 208,506 cells populating the normal tissues or early to metastatic stage cancer in 44 patients, we identify a cancer cell subtype deviating from the normal differentiation trajectory and dominating the metastatic stage. In all stages, the stromal and immune cell dynamics reveal ontological and functional changes that create a pro-tumoral and immunosuppressive microenvironment. Normal resident myeloid cell populations are gradually replaced with monocyte-derived macrophages and dendritic cells, along with T-cell exhaustion. This extensive single-cell analysis enhances our understanding of molecular and cellular dynamics in metastatic lung cancer and reveals potential diagnostic and therapeutic targets in cancer-microenvironment interactions. 1 Samsung Genome Institute, Samsung Medical Center, Seoul 06351, Korea.
    [Show full text]
  • View Dendritic Cell Development Poster
    Overview of Dendritic Cell Development Lineage–, CD45+, Common CD117 (c-kit) Common MHCII+, CD11c+ – + CD207 (Langerin) Myeloid CD117 (c-kit) Lineage , CD45 , Myeloid Progenitor MHCII (HLA-DR)+, CD11c+ Progenitor CD324 (E-Cadherin) Human Mouse CD326 (EpCAM) CD207 (Langerin) TGFb1 Cells CD11b, CD115 Cells CD14 Monocyte CD324 (E-Cadherin) Monocyte M-CSF CD11b – + Ly6C Langerhans CD24 Lineage , CD45 , M-CSF CD326 (EpCAM) MHCII (HLA-DR)+, CD11c+ Langerhans CD11blo Zbtb46– Cells CD172a (Sirp-α) CD16 CD1ahi, CD1c CD205 (DEC-205) Cells CSF F4/80 CD64 CD172a (Sirp-α) Lineage–, CD45+, FLT3L TLR3, TLR11 CD1a, CD1c Inflammatory CD369 (Dectin-1/CLEC7A) MHCII+, CD11c+ +/– CSF IL-15 CD8–, CD14– CD11b, CD14 CD371 (CLEC12A) CD64 Monocyte- FLT3L Inflammatory CD370 (Clec9a)– CD172a (Sirp-α) IL-15 CLEC6A CD11b derived lo Monocyte- CD206, CD209 (DC-SIGN) TLR1, TLR2, TLR3 , TLR6 CD209a (DC-SIGN) CD367 (DCIR/CLEC4A) DCs CD14– CD272 (BTLA)lo derived CD369 (Dectin-1/CLEC7A) DCs Common Ly-6C – + CD371 (CLEC12A) CD117 (c-kit) Lineage , CD45 , IL-1β, IL-6, IL-10, TLR1-6, TLR7-8, TLR10 Dendritic + lo CLEC6A – – CD135/FLT3 MHCII , CD11c IL-12, IL-23, TNF CD8a , CD14 IL-1β, IL-6 IL-10, Precursor TLR3lo, TLR4, TLR7, TLR8 CD45R (B220) IL-12, IL-23, TNF Plasmacytoid CD207 (Langerin)– Cells CD317 (BST-2) Common Lineage–, CD45+, FLT3L DCs Lineage–, CD45+, + Ly6C + lo/– CD207 IFN Type I + + Dendritic CD135/FLT3 MHCII (HLA-DR) , CD11c Lineage–, CD45+, IRF7, IRF8, BATF3hi Siglec-H MHCII (HLA-DR) , CD11c hi – + CD123 + + Dermal SpiB, Zbtb46 CD1a, CD64 CD1a Precursor CD117 (c-kit)
    [Show full text]
  • CD Markers Are Routinely Used for the Immunophenotyping of Cells
    ptglab.com 1 CD MARKER ANTIBODIES www.ptglab.com Introduction The cluster of differentiation (abbreviated as CD) is a protocol used for the identification and investigation of cell surface molecules. So-called CD markers are routinely used for the immunophenotyping of cells. Despite this use, they are not limited to roles in the immune system and perform a variety of roles in cell differentiation, adhesion, migration, blood clotting, gamete fertilization, amino acid transport and apoptosis, among many others. As such, Proteintech’s mini catalog featuring its antibodies targeting CD markers is applicable to a wide range of research disciplines. PRODUCT FOCUS PECAM1 Platelet endothelial cell adhesion of blood vessels – making up a large portion molecule-1 (PECAM1), also known as cluster of its intracellular junctions. PECAM-1 is also CD Number of differentiation 31 (CD31), is a member of present on the surface of hematopoietic the immunoglobulin gene superfamily of cell cells and immune cells including platelets, CD31 adhesion molecules. It is highly expressed monocytes, neutrophils, natural killer cells, on the surface of the endothelium – the thin megakaryocytes and some types of T-cell. Catalog Number layer of endothelial cells lining the interior 11256-1-AP Type Rabbit Polyclonal Applications ELISA, FC, IF, IHC, IP, WB 16 Publications Immunohistochemical of paraffin-embedded Figure 1: Immunofluorescence staining human hepatocirrhosis using PECAM1, CD31 of PECAM1 (11256-1-AP), Alexa 488 goat antibody (11265-1-AP) at a dilution of 1:50 anti-rabbit (green), and smooth muscle KD/KO Validated (40x objective). alpha-actin (red), courtesy of Nicola Smart. PECAM1: Customer Testimonial Nicola Smart, a cardiovascular researcher “As you can see [the immunostaining] is and a group leader at the University of extremely clean and specific [and] displays Oxford, has said of the PECAM1 antibody strong intercellular junction expression, (11265-1-AP) that it “worked beautifully as expected for a cell adhesion molecule.” on every occasion I’ve tried it.” Proteintech thanks Dr.
    [Show full text]
  • Insights Into Interactions of Mycobacteria with the Host Innate
    This is an open access article published under a Creative Commons Attribution (CC-BY) License, which permits unrestricted use, distribution and reproduction in any medium, provided the author and source are cited. Articles pubs.acs.org/acschemicalbiology Insights into Interactions of Mycobacteria with the Host Innate Immune System from a Novel Array of Synthetic Mycobacterial Glycans † ‡ † † † † Ruixiang Blake Zheng, Sabine A. F. Jegouzo,́ Maju Joe, Yu Bai, Huu-Anh Tran, Ke Shen, † † † † § § Jörn Saupe, Li Xia, Md. Faiaz Ahmed, Yu-Hsuan Liu, Pratap Subhashrao Patil, Ashish Tripathi, § ‡ † ‡ Shang-Cheng Hung, Maureen E. Taylor,*, Todd L. Lowary,*, and Kurt Drickamer*, † Department of Chemistry and Alberta Glycomics Centre, University of Alberta, Edmonton, AB T6G 2G2, Canada ‡ Department of Life Sciences, Imperial College, London SW7 2AZ, United Kingdom § Genomics Research Centre, Academia Sinica, Nangang, Taipei 11529, Taiwan *S Supporting Information ABSTRACT: An array of homogeneous glycans representing all the major carbohydrate structures present in the cell wall of the human pathogen Mycobacterium tuberculosis and other mycobacteria has been probed with a panel of glycan-binding receptors expressed on cells of the mammalian innate immune system. The results provide an overview of interactions between mycobacterial glycans and receptors that mediate uptake and survival in macrophages, dendritic cells, and sinusoidal endothelial cells. A subset of the wide variety of glycan structures present on mycobacterial surfaces interact with cells of the innate immune system through the receptors tested. Endocytic receptors, including the mannose receptor, DC-SIGN, langerin, and DC-SIGNR (L-SIGN), interact predominantly with mannose-containing caps found on the mycobacterial polysaccharide lipoarabinomannan. Some of these receptors also interact with phosphatidyl-myo-inositol mannosides and mannose-containing phenolic glycolipids.
    [Show full text]
  • Gene List HTG Edgeseq Immuno-Oncology Assay
    Gene List HTG EdgeSeq Immuno-Oncology Assay Adhesion ADGRE5 CLEC4A CLEC7A IBSP ICAM4 ITGA5 ITGB1 L1CAM MBL2 SELE ALCAM CLEC4C DST ICAM1 ITGA1 ITGA6 ITGB2 LGALS1 MUC1 SVIL CDH1 CLEC5A EPCAM ICAM2 ITGA2 ITGAL ITGB3 LGALS3 NCAM1 THBS1 CDH5 CLEC6A FN1 ICAM3 ITGA4 ITGAM ITGB4 LGALS9 PVR THY1 Apoptosis APAF1 BCL2 BID CARD11 CASP10 CASP8 FADD NOD1 SSX1 TP53 TRAF3 BCL10 BCL2L1 BIRC5 CASP1 CASP3 DDX58 NLRP3 NOD2 TIMP1 TRAF2 TRAF6 B-Cell Function BLNK BTLA CD22 CD79A FAS FCER2 IKBKG PAX5 SLAMF1 SLAMF7 SPN BTK CD19 CD24 EBF4 FASLG IKBKB MS4A1 RAG1 SLAMF6 SPI1 Cell Cycle ABL1 ATF1 ATM BATF CCND1 CDK1 CDKN1B NCL RELA SSX1 TBX21 TP53 ABL2 ATF2 AXL BAX CCND3 CDKN1A EGR1 REL RELB TBK1 TIMP1 TTK Cell Signaling ADORA2A DUSP4 HES1 IGF2R LYN MAPK1 MUC1 NOTCH1 RIPK2 SMAD3 STAT5B AKT3 DUSP6 HES5 IKZF1 MAF MAPK11 MYC PIK3CD RNF4 SOCS1 STAT6 BCL6 ELK1 HEY1 IKZF2 MAP2K1 MAPK14 NFATC1 PIK3CG RORC SOCS3 SYK CEBPB EP300 HEY2 IKZF3 MAP2K2 MAPK3 NFATC3 POU2F2 RUNX1 SPINK5 TAL1 CIITA ETS1 HEYL JAK1 MAP2K4 MAPK8 NFATC4 PRKCD RUNX3 STAT1 TCF7 CREB1 FLT3 HMGB1 JAK2 MAP2K7 MAPKAPK2 NFKB1 PRKCE S100B STAT2 TYK2 CREB5 FOS HRAS JAK3 MAP3K1 MEF2C NFKB2 PTEN SEMA4D STAT3 CREBBP GATA3 IGF1R KIT MAP3K5 MTDH NFKBIA PYCARD SMAD2 STAT4 Chemokine CCL1 CCL16 CCL20 CCL25 CCL4 CCR2 CCR7 CX3CL1 CXCL12 CXCL3 CXCR1 CXCR6 CCL11 CCL17 CCL21 CCL26 CCL5 CCR3 CCR9 CX3CR1 CXCL13 CXCL5 CXCR2 MST1R CCL13 CCL18 CCL22 CCL27 CCL7 CCR4 CCRL2 CXCL1 CXCL14 CXCL6 CXCR3 PPBP CCL14 CCL19 CCL23 CCL28 CCL8 CCR5 CKLF CXCL10 CXCL16 CXCL8 CXCR4 XCL2 CCL15 CCL2 CCL24 CCL3 CCR1 CCR6 CMKLR1 CXCL11 CXCL2 CXCL9 CXCR5
    [Show full text]
  • Diagnostic Accuracy of a Novel Point-Of-Care Urine
    Early View Original article Diagnostic accuracy of a novel point-of-care urine lipoarabinomannan assay for the detection of tuberculosis among adult outpatients in Zambia: a prospective cross-sectional study Monde Muyoyeta, Andrew D. Kerkhoff, Lophina Chilukutu, Emmanuel Moreau, Samuel G. Schumacher, Morten Ruhwald Please cite this article as: Muyoyeta M, Kerkhoff AD, Chilukutu L, et al. Diagnostic accuracy of a novel point-of-care urine lipoarabinomannan assay for the detection of tuberculosis among adult outpatients in Zambia: a prospective cross-sectional study. Eur Respir J 2021; in press (https://doi.org/10.1183/13993003.03999-2020). This manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Copyright ©The authors 2021. This version is distributed under the terms of the Creative Commons Attribution Licence 4.0. Diagnostic accuracy of a novel point-of-care urine lipoarabinomannan assay for the detection of tuberculosis among adult outpatients in Zambia: a prospective cross-sectional study Authors: Monde Muyoyeta, MBChB, PhD*# Centre for Infectious Diseases research in Zambia Lusaka, Zambia Andrew D. Kerkhoff, MD, PhD# Division of HIV, Infectious Diseases and Global Medicine, Zuckerberg San Francisco General Hospital and Trauma Center, University of California San Francisco, San Francisco, CA Lophina Chilukutu, Dip. Centre for Infectious Diseases research in Zambia Lusaka, Zambia Emmanuel Moreau, PhD Foundation for Innovative New diagnostics Samuel G.
    [Show full text]
  • Biosynthesis of Mycobacterial Lipoarabinomannan: Role of a Branching Mannosyltransferase
    Biosynthesis of mycobacterial lipoarabinomannan: Role of a branching mannosyltransferase Devinder Kaur*, Stefan Berg*, Premkumar Dinadayala*, Brigitte Gicquel†, Delphi Chatterjee*, Michael R. McNeil*, Varalakshmi D. Vissa*, Dean C. Crick*, Mary Jackson†, and Patrick J. Brennan*‡ *Department of Microbiology, Immunology, and Pathology, Colorado State University, Fort Collins, CO 80523; and †Unite de Genetique Mycobacterienne, Institut Pasteur, 25 Rue du Dr. Roux, 75724 Paris Cedex 15, France Edited by Emil C. Gotschlich, The Rockefeller University, New York, NY, and approved July 21, 2006 (received for review April 13, 2006) Lipoarabinomannan (LAM), one of the few known bacterial gly- been believed, although not empirically demonstrated, that both cosylphosphoinositides (GPIs), occurs in various structural forms in LM and LAM have their origins in the PIMs, because all contain Mycobacterium species. It has been implicated in key aspects of the a phosphatidylinositol (PI) moiety (5, 6). The first step in PIM physiology of Mycobacterium tuberculosis and the immunology synthesis involves the transfer of a Manp residue to the 2 position and pathogenesis of tuberculosis. Yet, little is known of the of the myo-inositol ring of PI to form PIM1, catalyzed by PimA biosynthesis of LAM. A bioinformatics approach identified putative (7, 8). Biosynthesis proceeds by means of the sequential addition § integral membrane proteins, MSMEG4250 in Mycobacterium smeg- of Manp residues to PIM1 or its acylated counterpart (AcPIM1), matis and Rv2181 in M. tuberculosis, with 10 predicted transmem- catalyzed in part by PimB and PimC, to produce PIM species brane domains and a glycosyltransferase (GT) motif (DID), features having from two (PIM2) to three (PIM3) Manp residues (9, 10).
    [Show full text]
  • Assessing Various Control Samples for Microarray Gene Expression Profiling of Laryngeal Squamous Cell Carcinoma
    biomolecules Communication Assessing Various Control Samples for Microarray Gene Expression Profiling of Laryngeal Squamous Cell Carcinoma Adam Ustaszewski 1 , Magdalena Kostrzewska-Poczekaj 1, Joanna Janiszewska 1 , Malgorzata Jarmuz-Szymczak 1,2, Malgorzata Wierzbicka 1,3 , Joanna Marszal 3 , Reidar Grénman 4 and Maciej Giefing 1,* 1 Institute of Human Genetics, Polish Academy of Sciences, Strzeszy´nska32, 60-479 Pozna´n,Poland; [email protected] (A.U.); [email protected] (M.K.-P.); [email protected] (J.J.); [email protected] (M.J.-S.); [email protected] (M.W.) 2 Department of Oncology, Hematology and Bone Marrow Transplantation, Poznan University of Medical Sciences, 61-001 Pozna´n,Poland 3 Department of Otolaryngology and Laryngological Oncology, Pozna´nUniversity of Medical Sciences, 60-355 Pozna´n,Poland; [email protected] 4 Department of Otorhinolaryngology-Head and Neck Surgery, University of Turku and Turku University Hospital, 20520 Turku, Finland; seija.grenman@tyks.fi * Correspondence: maciej.giefi[email protected]; Tel.: +48-61-6579-138 Abstract: Selection of optimal control samples is crucial in expression profiling tumor samples. To address this issue, we performed microarray expression profiling of control samples routinely used in head and neck squamous cell carcinoma studies: human bronchial and tracheal epithelial cells, Citation: Ustaszewski, A.; squamous cells obtained by laser uvulopalatoplasty and tumor surgical margins. We compared Kostrzewska-Poczekaj, M.; the results using multidimensional scaling and hierarchical clustering versus tumor samples and Janiszewska, J.; Jarmuz-Szymczak, M.; laryngeal squamous cell carcinoma cell lines. A general observation from our study is that the Wierzbicka, M.; Marszal, J.; Grénman, R.; Giefing, M.
    [Show full text]
  • Distribution Patterns of Dendritic Cells and T Cells in Diffuse Large B-Cell
    Imaging, Diagnosis, Prognosis Distribution Patterns of Dendritic Cells and T Cells in Diffuse Large B-Cell Lymphomas Correlate with Prognoses Kung-Chao Chang,1, 2 Guan-Cheng Huang,3 DanJones,5 and Ya-Hui Lin4 Abstract Purpose: Diffuse large B-cell lymphoma (DLBCL), the most common subtype of non-Hodgkin’s lymphomas, accounts for 30% to 40% of all lymphoma cases. However, long-term survival by current chemotherapy was achieved in only 40% of patients, warranting the development of novel therapeutic strategies including T-cell immunotherapy. However, the level of baseline immune activation in DLBCL is unclear. Experimental Design: The density and distribution of dendritic cells and Tcells in 48 cases of primary DLBCL was evaluated by immunohistochemistry. Results: Increased numbers of intratumoral CD1a+ dendritic cells and increased S100+ cells and CD45RO+ T cells around the edges of the tumors were seen in 10 of 48 (21%), 9 of 48 (19%), and 10 of 48 (21%) cases and these were correlated with a favorable prognosis (P =0.015; P =0.070,andP = 0.017, respectively), along with increased granzyme B+ T cells in tumor beds (P = 0.013). Increased peritumoral T cells were correlated with tumor expression of HL A-DR (r = 0.446; P = 0.002). Extranodal lymphomas showed fewer tumor-associated CD45RO+ Tcells (r =-0.407;P = 0.001) and less conspicuous dendritic cell infiltrates. Conclusions: In DLBCL, the presence of baseline antitumor immune response is associated with favorable clinical outcome, and thus adjuvant T-cell immunotherapy may further boost treatment responses. The most common subtype of non-Hodgkin’s lymphoma is In animal models, the mice, which were immunized with diffuse large B-cell lymphoma (DLBCL; ref.
    [Show full text]